WaveMan
WaveMan · Company
ABEO · Abeona Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ABEO Abeona Therapeutics (ABEO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000318306
Quote by TradingView
Activist 13DForm 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
78
13F, latest reported quarter

What the filings say about ABEO

Insiders, 180 days
-$2.2M net sold
8 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$296.4K
5 notices
Activist stakes (13D), 180 days
1 filing
Largest: 6.1% of the class

Abeona Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ABEONA THERAPEUTICS INC. insiders sold a net $2.2M of stock across 98 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Vasanthavada Madhav
Chief Commercial Officer
SELL
2026-09-29 SEC
4,902
$25.3K
-17.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jul 9, 2026.
  • The trade is 1.7% of the 285,721 shares held after it.
  • 4 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Vasanthavada Madhav sold about $25.3K of ABEO on Sep 29, 2026; 4 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
Seshadri Vishwas
Chief Executive Officer
SELL
2026-09-29 SEC
19,608
$101.1K
-17.9%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (3 buys, 12 sales), the last on Jul 9, 2026.
  • +28.5% median (+32.7% mean) 90-day return after 3 previous buys.
  • The trade is 1.5% of the 1,286,500 shares held after it.
  • 4 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Seshadri Vishwas sold about $101.1K of ABEO on Sep 29, 2026; 4 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
Vazzano Joseph Walter
Chief Financial Officer
SELL
2026-09-29 SEC
9,191
$47.4K
-17.9%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (4 buys, 12 sales), the last on Jul 21, 2026.
  • +24.0% median (+13.4% mean) 90-day return after 3 previous buys.
  • The trade is 1.9% of the 482,888 shares held after it.
  • 4 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Vazzano Joseph Walter sold about $47.4K of ABEO on Sep 29, 2026; 4 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
O'Malley Brendan M.
SVP, Chief Legal Officer
SELL
2026-09-29 SEC
6,727
$34.7K
-17.9%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (4 buys, 13 sales), the last on Jul 9, 2026.
  • +9.9% median (+9.0% mean) 90-day return after 4 previous buys.
  • The trade is 1.6% of the 421,226 shares held after it.
  • 4 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Legal Officer O'Malley Brendan M. sold about $34.7K of ABEO on Sep 29, 2026; 4 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
Alvino Mark
Director
SELL
2026-09-01 SEC
15,000
$88.0K
-27.6%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on May 22, 2026.
  • The trade is 24.2% of the 62,065 shares held after it.
  • 4 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Alvino Mark sold about $88.0K of ABEO on Sep 1, 2026; 4 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
98 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 93 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.2M over 180 days
-$296.4K over 90 days
below 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
78 funds bought in last quarter
more than 59% of Pharma & Biotech
Revenue
+66.3% year over year
more than 81% of Pharma & Biotech
Margin
1223.1% net margin
the highest in Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
46.8% of the float short (float per yahoo 2026-10-26) · 11.6 days to cover · settled 2026-09-30
more than 99% of Pharma & Biotech
The situation: each line is one rule over one dataset
James Russell Revocable Trust disclosed a 5%+ stake (6.1%) in the last six months.
What changed in the last 30 days
Oct 23James Russell Revocable Trust filed a 13D for 6.1%
Oct 23James Russell filed a 13D for 6.1%
Sep 29Chief Executive Officer Seshadri Vishwas sold $101.1K (Sep 29)
Sep 29Officer Seshadri Vishwas filed to sell $101.1K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 29Chief Financial Officer Vazzano Joseph Walter sold $47.4K (Sep 29)

Watch ABEO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.3%12M
-23%-3%+18%+38%2025-102025-122026-022026-042026-062026-082026-10 2026-07-09 · Seshadri Vishwas sold $473.3K2026-01-22 · Seshadri Vishwas sold $372.2K2026-07-09 · Vazzano Joseph Walter sold $173.3K2026-06-09 · Seshadri Vishwas sold $169.2K2026-05-15 · Crombez Eric sold $144.6K2026-06-09 · Vazzano Joseph Walter sold $138.2K2025-12-29 · Seshadri Vishwas sold $132.8K2026-06-08 · Seshadri Vishwas sold $132.6K2026-03-31 · Seshadri Vishwas sold $131.3K2026-06-15 · Silverstein Christine Berni sold $103.7K2026-02-02 · Silverstein Christine Berni sold $102.2K2026-09-29 · Seshadri Vishwas sold $101.1K2026-01-22 · Vazzano Joseph Walter sold $99.5K2026-02-02 · Alland Leila sold $92.0K2026-09-01 · Alvino Mark sold $88.0K2026-07-09 · Vasanthavada Madhav sold $87.8K2026-07-09 · O'Malley Brendan M. sold $83.9K2026-02-02 · Crombez Eric sold $82.9K2026-02-02 · Wuchterl Donald A. sold $75.4K2026-01-22 · O'Malley Brendan M. sold $72.4K2026-06-09 · Vazzano Joseph Walter sold $71.1K2025-11-13 · Alvino Mark sold $71.1K2026-01-21 · Alvino Mark sold $70.6K2026-01-22 · Vasanthavada Madhav sold $66.7K2026-06-30 · Alland Leila sold $65.1K2026-06-08 · Vazzano Joseph Walter sold $55.8K2026-09-29 · Vazzano Joseph Walter sold $47.4K2026-05-22 · Alvino Mark sold $35.5K2026-09-29 · O'Malley Brendan M. sold $34.7K2026-06-09 · O'Malley Brendan M. sold $33.4K2026-05-11 · Vasanthavada Madhav sold $33.1K2026-06-09 · Vasanthavada Madhav sold $28.9K2026-06-08 · O'Malley Brendan M. sold $26.2K2026-09-29 · Vasanthavada Madhav sold $25.3K2026-06-08 · Vasanthavada Madhav sold $22.6K2026-02-02 · Alvino Mark sold $10.2K2026-07-21 · Vazzano Joseph Walter sold $9.7K2026-03-16 · Vazzano Joseph Walter sold $3.7K2026-10-23 · James Russell Revocable Trust filed a 5%+ stake (6.1%)2026-10-23 · James Russell filed a 5%+ stake (6.1%)2026-09-29 · O'Malley Brendan M. filed to sell $34.7K2026-09-29 · Vasanthavada Madhav filed to sell $25.3K2026-09-29 · Seshadri Vishwas filed to sell $101.1K2026-09-29 · Vazzano Joseph Walter filed to sell $47.4K2026-09-01 · Alvino Mark filed to sell $88.0K2026-07-09 · O'Malley Brendan M. filed to sell $83.9K2026-07-09 · Vazzano Joseph Walter filed to sell $173.3K2026-07-09 · Vasanthavada Madhav filed to sell $87.8K2026-07-09 · Seshadri Vishwas filed to sell $473.3K2026-07-06 · Silverstein Christine Berni filed to sell $640.8K
Insider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ABEO: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
10,272,980 sh
$63.5M
BlackRock, Inc.
3,352,474 sh
$20.7M
Cable Car Capital, LP
3,007,329 sh
$18.6M
AIGH Capital Management LLC
2,987,000 sh
$18.5M
VANGUARD CAPITAL MANAGEMENT LLC
2,211,433 sh
$13.7M

Congress trades in ABEO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
James Russell Revocable Trust
Activist 13D · 2026-10-23
6.1%
James Russell
Activist 13D · 2026-10-23
6.1%

ABEO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
O'Malley Brendan M.
Filed 2026-09-29
$34.7K
Vasanthavada Madhav
Filed 2026-09-29
$25.3K
Seshadri Vishwas
Filed 2026-09-29
$101.1K
Vazzano Joseph Walter
Filed 2026-09-29
$47.4K
Alvino Mark
Filed 2026-09-01
$88.0K

ABEO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$2.1M position · as of 2026-06-30
2.8%
NORTH SQUARE KENNEDY MICROCAP FUND
$197.8K position · as of 2026-05-31
0.6%
Harbor Human Capital Factor US Small Cap ETF
$245.9K position · as of 2026-07-31
0.1%
Small Cap Value Fund
$713.9K position · as of 2026-06-30
0.1%
WisdomTree U.S. SmallCap Fund
$589.8K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$896.8K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
1 active
1
Phase 4
1 active
2
Not applicable
2 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.0M
$4.0M
$1.6M
+71%
n/a
2024
$3.5M
$4.0M
$1.5M
+81%
n/a
2023
$2.8M
$3.5M
$1.3M
+63%
n/a
2022
$1.5M
$1.3M
$656.5K
-63%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $2.2M sold by insiders over 180 days, 78 funds added last quarter, $296.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ABEO financials

Revenue growth
+66.3%
XBRL, annual
Net margin
1223.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$25.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-804.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$81.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.12x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-5.10x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-140.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-96.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-45.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$205.2M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-33.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$5.8Mn/a$3.5M$1.4M
Operating income-$89.4M-$64.2M-$47.1M-$50.9M
Net income-$71.2M$63.7M$54.2M-$39.7M
EPS (diluted)1.01-1.55-2.53-5.53
Operating cash flow-$76.3M-$56.0M-$37.0M-$43.5M
Cash$78.4M$23.4M$14.5M$14.2M
Long-term debt$7.8M$13.0Mn/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

ABEO Stock Sonar score 6/7 axes

Find similar shapesCompare

ABEO ranks highest on growth (68th percentile) and institutional and government (59th), and lowest on risk and compliance (9th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
35
Inputs
  • Return on equity-140.8% · 24 pct, sector of 545
  • Return on assets-96.4% · 25 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-45.6% · 54 pct, sector of 576
Financial health
40
Inputs
  • Debt to equity0.12x · 52 pct, sector of 352
  • Cash flow to debt-5.10x · 28 pct, sector of 371
Growth
68
Inputs
  • Revenue growth, YoY+66.3% · 81 pct, sector of 505
  • Backlog growth, YoY+0.0% · 54 pct, sector of 40
Insider conviction
14
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.2M · 28 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
59
Inputs
  • Funds adding, latest quarter78 · 59 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
9
Inputs
  • Short interest, % of float+46.8% · 0 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+19.4% · 18 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ABEO filings, in plain words

Are Abeona Therapeutics insiders buying or selling ABEO?

In the 180 days to 2026-10-27, Abeona Therapeutics insiders were net sellers, a net $2.2M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of ABEO?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $296.4K of stock; the latest, by O'Malley Brendan M., was filed 2026-09-29.

Read the full summary

In the 180 days to 2026-10-27, Abeona Therapeutics insiders were net sellers of ABEO, a net $2.2M across purchases and sales reported on Form 4 by 8 sellers. None of the 24 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $296.4K of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 6.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies